A brand new class of epilepsy medicines primarily based on an ingredient derived from marijuana might be accessible as quickly as within the second half of 2018 within the United States pending Food and Drug Administration approval.

Officials from GW Pharmaceuticals, the corporate that developed the drug, on Wednesday introduced promising outcomes from a research on 171 sufferers randomized into remedy and placebo teams.

Members of the group, who have been 2 to 55 years of age, have a situation known as Lennox-Gastaut Syndrome and have been affected by seizures that weren’t being managed by current medication. 

Click here to read the complete article

MagNerd.com via 420Intel.com

Recent News Articles

Tuesday May 21

Poll: Most of Illinois says marijuana should be legal - Cannabis News

in Politics

by Bruce Kennedy - Editor in Chief

A new poll by Global Strategy Group on behalf of Think Big Illinois, says a…

928 hits

Tuesday May 21

New Report Says US Cannabis Market Could Hit $22.7B By 2023 - Cannabis News

in Finance

by Bruce Kennedy - Editor in Chief

A new report projects the cannabis market in the United States will reach $22.7 billion…

1099 hits

Tuesday May 21

We May Finally Know Where the Cannabis Plant Originated - Cannabis News

in Science

by Bruce Kennedy - Editor in Chief

Cannabis may have originated high on the Tibetan Plateau, according to an analysis of fossil…

1332 hits

Tuesday May 21

NFL, NFLPA will reportedly study marijuana as potential pain-management tool for players - Cannabis News

in Sports

by Bruce Kennedy - Editor in Chief

With talks of a new collective bargaining agreement underway, the NFL and NFL Players Association…

1385 hits

Wednesday May 22

Marijuana sales east of Mississippi poised to rival western markets - Cannabis News

in Finance

by Bruce Kennedy - Editor in Chief

The cannabis industry in the United States has long been centered around such states as…

1063 hits